<!DOCTYPE html>
<html lang="" xml:lang="">
<head>

  <meta charset="utf-8" />
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  <title>97039 - GLOBAL HEALTH, ANTIMICROBIAL DRUGS AND VACCINES</title>
  <meta name="description" content="97039 - GLOBAL HEALTH, ANTIMICROBIAL DRUGS AND VACCINES" />
  <meta name="generator" content="bookdown 0.24 and GitBook 2.6.7" />

  <meta property="og:title" content="97039 - GLOBAL HEALTH, ANTIMICROBIAL DRUGS AND VACCINES" />
  <meta property="og:type" content="book" />
  
  
  
  

  <meta name="twitter:card" content="summary" />
  <meta name="twitter:title" content="97039 - GLOBAL HEALTH, ANTIMICROBIAL DRUGS AND VACCINES" />
  
  
  

<meta name="author" content="Russell E. Lewis, Associate Professor, Infectious Diseases, University of Bologna" />


<meta name="date" content="2022-11-26" />

  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <meta name="apple-mobile-web-app-capable" content="yes" />
  <meta name="apple-mobile-web-app-status-bar-style" content="black" />
  
  

<link rel="next" href="why-has-antibiotic-discovery-faltered-in-recent-years.html"/>
<script src="assets/header-attrs-2.11/header-attrs.js"></script>
<script src="assets/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<script src="https://cdn.jsdelivr.net/npm/fuse.js@6.4.6/dist/fuse.min.js"></script>
<link href="assets/gitbook-2.6.7/css/style.css" rel="stylesheet" />
<link href="assets/gitbook-2.6.7/css/plugin-table.css" rel="stylesheet" />
<link href="assets/gitbook-2.6.7/css/plugin-bookdown.css" rel="stylesheet" />
<link href="assets/gitbook-2.6.7/css/plugin-highlight.css" rel="stylesheet" />
<link href="assets/gitbook-2.6.7/css/plugin-search.css" rel="stylesheet" />
<link href="assets/gitbook-2.6.7/css/plugin-fontsettings.css" rel="stylesheet" />
<link href="assets/gitbook-2.6.7/css/plugin-clipboard.css" rel="stylesheet" />








<link href="assets/anchor-sections-1.0.1/anchor-sections.css" rel="stylesheet" />
<script src="assets/anchor-sections-1.0.1/anchor-sections.js"></script>



<style type="text/css">
/* Used with Pandoc 2.11+ new --citeproc when CSL is used */
div.csl-bib-body { }
div.csl-entry {
  clear: both;
}
.hanging div.csl-entry {
  margin-left:2em;
  text-indent:-2em;
}
div.csl-left-margin {
  min-width:2em;
  float:left;
}
div.csl-right-inline {
  margin-left:2em;
  padding-left:1em;
}
div.csl-indent {
  margin-left: 2em;
}
</style>

</head>

<body>



  <div class="book without-animation with-summary font-size-2 font-family-1" data-basepath=".">

    <div class="book-summary">
      <nav role="navigation">

<ul class="summary">
<li class="chapter" data-level="" data-path="the-growing-crises-of-antibiotic-development.html"><a href="the-growing-crises-of-antibiotic-development.html"><i class="fa fa-check"></i>The growing crises of antibiotic development</a></li>
<li class="chapter" data-level="" data-path="why-has-antibiotic-discovery-faltered-in-recent-years.html"><a href="why-has-antibiotic-discovery-faltered-in-recent-years.html"><i class="fa fa-check"></i>Why has antibiotic discovery faltered in recent years?</a>
<ul>
<li class="chapter" data-level="" data-path="why-has-antibiotic-discovery-faltered-in-recent-years.html"><a href="why-has-antibiotic-discovery-faltered-in-recent-years.html#scientific-challenges"><i class="fa fa-check"></i>Scientific challenges</a></li>
<li class="chapter" data-level="" data-path="why-has-antibiotic-discovery-faltered-in-recent-years.html"><a href="why-has-antibiotic-discovery-faltered-in-recent-years.html#antibiotic-regulatory-approval"><i class="fa fa-check"></i>Antibiotic Regulatory approval</a></li>
<li class="chapter" data-level="" data-path="why-has-antibiotic-discovery-faltered-in-recent-years.html"><a href="why-has-antibiotic-discovery-faltered-in-recent-years.html#economic-challenges"><i class="fa fa-check"></i>Economic challenges</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="what-strategies-can-be-used-to-stimulate-antibiotics-development.html"><a href="what-strategies-can-be-used-to-stimulate-antibiotics-development.html"><i class="fa fa-check"></i>What strategies can be used to stimulate antibiotics development</a></li>
</ul>

      </nav>
    </div>

    <div class="book-body">
      <div class="body-inner">
        <div class="book-header" role="navigation">
          <h1>
            <i class="fa fa-circle-o-notch fa-spin"></i><a href="./">97039 - GLOBAL HEALTH, ANTIMICROBIAL DRUGS AND VACCINES</a>
          </h1>
        </div>

        <div class="page-wrapper" tabindex="-1" role="main">
          <div class="page-inner">

            <section class="normal" id="section-">
<div id="header">
<h1 class="title">97039 - GLOBAL HEALTH, ANTIMICROBIAL DRUGS AND VACCINES</h1>
<h2 class="subtitle"><em>The Crisis in Antibiotic Development</em></h2>
<p class="author"><em>Russell E. Lewis, Associate Professor, Infectious Diseases, University of Bologna</em></p>
<p class="date"><em>11/26/2022</em></p>
</div>
<div id="the-growing-crises-of-antibiotic-development" class="section level2 unnumbered">
<h2>The growing crises of antibiotic development</h2>
<p>In module 1, we discussed the history of antibiotic discovery and the current challenges with antimicrobial resistance that has been amplified by the lack of development of new antibiotics. In this module, we will examine the scientific and economic challenges associated with antibiotic development, and compare and contrast strategies that have been proposed to stimulate development of new antibiotics.</p>
<p>As we discussed previously, antibiotic discovery began to slow in the 1980’s leading to a discovery void in new molecular entities (NMEs) since the 1990s. This lack of antibiotic innovation occurred at a critical period when antibiotic resistance, particularly to many front-line beta-lactam antibiotics began to increase rapidly due to the emergence and worldwide diffusion of new forms of enzymatic (beta-lactamase) resistance to antibiotics. These bacterial enzymes can be broadly classified as:</p>
<ul>
<li>Narrow-spectrum beta-lactamases, which act on penicillins and first-generation cephalosporins (e.g., TEM-1 and 2, SHV-1, cephalosporinases, OXA-type enzymes</li>
<li>Extended-spectrum beta-lactamases (ESBLs), which act on penicillins and all four generations of cephalosporins (SHV-2, SHV-5, SHV-7, SHV-12, TEM-10, TEM-12, TEM-26, CTX-M, OXA-type ESBLs)</li>
<li>Carbapenemases, which act on penicillins, all four generations of cephalosporins, and carbapenems (KPC, NDM-1, VIM and IMP carbapenemases, OXA-type carbapenemases).</li>
</ul>
<p>These beta-lactamases are problematic because they have a low barrier for creating resistance to multiple agents that are considered first and second line therapies of choice for common respiratory, abdominal, and genital-urinary tract infect infections. Indeed, single amino acid changes in the enzymes often can change their ability to hydrolyze new antibiotics. Additionally, many of these enzymes are encoded on spread on plasmids (mobile genetic elements that can be passed from one bacterial species to another) that harbour additional resistance mechanisms to other classes resulting in rapid dissemination of multidrug resistance.</p>
<figure>
<center>
<p><img src="images/betalactamases.png" width="800" /></p>
<figcaption>
<p><strong>Figure 1. Increase in numbers of group 1, 2, and 3 beta-lactamases from 1970 to 2009</strong>. Figure is from Bush and Jacoby<span class="citation"><sup>1</sup></span></p>
</figcaption>
</center>
</figure>
<p>As discussed in module 1, the WHO in 2017 convened a group of experts to prioritize the need for new drugs to treat antibiotic- resistant bacteria. The WHO assigned the highest priority to antibacterial drug research and development for the Gram- negative bacteria <em>Acinetobacter</em>, <em>Pseudomonas</em> and species of <em>Enterobacterales</em> that are resistant to carbapenems and are usually extensively drug resistant (XDR).</p>
<p><strong>Table 1. WHO priority pathogens</strong></p>
</figcaption>
<table>
<colgroup>
<col width="13%" />
<col width="86%" />
</colgroup>
<thead>
<tr class="header">
<th align="left">Priority</th>
<th align="left">Pathogens included</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td align="left"><strong>Critical</strong></td>
<td align="left"><p><em>Acinetobacter baumannii</em> (Carbapenem-resistant)</p>
<p><em>Pseudomonas aeruginosa</em> (Carbapenem-resistant)</p>
<p>Enterbacterales (3rd generation cephalosporin, carbapenem-resistant)</p></td>
</tr>
<tr class="even">
<td align="left"><strong>High</strong></td>
<td align="left"><p><em>Enterococcus faecium</em>, vancomycin-resistant</p>
<p><em>Staphylococcus aureus</em>, methicillin-resistant, vancomycin intermediate and resistant</p>
<p><em>Helicobacter pylori</em>, clarithromycin-resistant</p>
<p><em>Campylobacter</em>, fluoroquinolone-resistant</p>
<p><em>Salmonella</em> spp., fluoroquinolone-resistant</p>
<p><em>Neisseria gonorrhoeae</em>, 3rd generation cephalosporin-resistant, fluoroquinolone-resistant</p></td>
</tr>
<tr class="odd">
<td align="left"><strong>Medium</strong></td>
<td align="left"><p><em>Streptococcus pneumoniae</em>, penicillin-non-susceptible</p>
<p><em>Haemophilus influenzae</em>, ampicillin-resistant</p>
<p><em>Shigella</em> spp., fluoroquinolone-resistant</p></td>
</tr>
</tbody>
</table>
<p><br>The same year, the WHO released a <a href="https://apps.who.int/iris/bitstream/handle/10665/330420/9789240000193-eng.pdf">clinical pipeline report</a>, which was updated in 2018 and 2019. The clinical pipeline reports analysed antibiotics and biologics in development according to their activity against the critical priority pathogens carbapenem resistant <em>Acinetobacter baumannii</em> (CRAB), carbapenem-resistant <em>Pseudomonas aeruginosa</em> (CRPA), extended spectrum beta-lactamase (ESBL) producing Enterobacterales and carbapenem resistant Enterobacterales (CRE). The level of innovation in the global clinical pipeline was assessed on the basis of the absence of pre-existing cross-resistance to currently used antibacterial drugs. The key findings from this report included:</p>
<blockquote>
<ul>
<li><p>The clinical pipeline remains insufficient to tackle the challenge of increasing emergence and spread of antimicrobial resistance.</p></li>
<li><p>It is primarily driven by small- or medium-sized enterprises (SMEs), with large pharmaceutical companies continuing to exit the field.</p></li>
<li><p>Eight new antibacterial agents have been approved since 1 July 2017, but overall, they have limited clinical benefits.</p></li>
<li><p>One new anti-tuberculosis (anti-TB) agent, pretomanid, developed by a not-for-profit organization, has been approved for use within a set drug-combination treatment for MDR TB.</p></li>
<li><p>The current clinical pipeline contains 50 antibiotics and combinations (with a new therapeutic entity) and 10 biologicals, of which 32 antibiotics are active against the WHO priority pathogens:</p>
<ul>
<li><p>Six of these agents fulfil at least one of the innovation criteria; only two of these are active against the critical MDR Gram-negative bacteria.</p></li>
<li><p>More than 40% of the pipeline targeting WHO priority pathogens consists of additional β-lactam and β-lactamase inhibitor (BLI) combinations, with a major gap in activity against metallo-βlactamase (MBL) producers.</p></li>
<li><p>The anti-TB and C. difficile antibacterial pipeline is more innovative than the WHO priority pathogens pipeline, with more than half of the antibiotics fulfilling all of the innovation criteria.</p></li>
</ul></li>
</ul>
</blockquote>
</div>
            </section>

          </div>
        </div>
      </div>

<a href="why-has-antibiotic-discovery-faltered-in-recent-years.html" class="navigation navigation-next navigation-unique" aria-label="Next page"><i class="fa fa-angle-right"></i></a>
    </div>
  </div>
<script src="assets/gitbook-2.6.7/js/app.min.js"></script>
<script src="assets/gitbook-2.6.7/js/clipboard.min.js"></script>
<script src="assets/gitbook-2.6.7/js/plugin-search.js"></script>
<script src="assets/gitbook-2.6.7/js/plugin-sharing.js"></script>
<script src="assets/gitbook-2.6.7/js/plugin-fontsettings.js"></script>
<script src="assets/gitbook-2.6.7/js/plugin-bookdown.js"></script>
<script src="assets/gitbook-2.6.7/js/jquery.highlight.js"></script>
<script src="assets/gitbook-2.6.7/js/plugin-clipboard.js"></script>
<script>
gitbook.require(["gitbook"], function(gitbook) {
gitbook.start({
"sharing": {
"github": false,
"facebook": true,
"twitter": true,
"linkedin": false,
"weibo": false,
"instapaper": false,
"vk": false,
"whatsapp": false,
"all": ["facebook", "twitter", "linkedin", "weibo", "instapaper"]
},
"fontsettings": {
"theme": "white",
"family": "sans",
"size": 2
},
"edit": {
"link": null,
"text": null
},
"history": {
"link": null,
"text": null
},
"view": {
"link": null,
"text": null
},
"download": null,
"search": false,
"toc": {
"collapse": "subsection"
},
"toolbar": {
"position": "static"
}
});
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    var src = "true";
    if (src === "" || src === "true") src = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-MML-AM_CHTML";
    if (location.protocol !== "file:")
      if (/^https?:/.test(src))
        src = src.replace(/^https?:/, '');
    script.src = src;
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>
</body>

</html>
